ARTICLE SUMMARY:
The entrance of non-traditional financing sources into clinical diagnostics has the potential to heat up a field that is already brimming with innovation, but also may distort valuations if the industry does not address business model and regulatory questions.
Superstar geneticists Jennifer Doudna, a professor of microbiology and cell biology at the University of California at Berkeley, and Jay Shendure, MD, PhD, a professor of genomic science at the University of Washington, got top billing at the annual meeting of the American Association for Clinical Chemistry (AACC) last month—interesting choices, given they work at the very cutting edge of genomics, in areas well outside the domain of today’s clinical laboratory.
